We are in the midst of a ‘psychedelic renaissance’. Not since the 1950s and early 1960s has there been so much interest in researching the therapeutic potential of psychedelics. The FDA approved a ketamine derivative for medicinal use in 2019, and has given both MDMA and psilocybin (the psycho-active ingredient in magic mushrooms) ‘breakthrough therapy’ status, putting the drugs on a fast track to approval in the US, with the UK likely to follow suit.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Unlock this article
You might disagree with half of it, but you’ll enjoy reading all of it. Try your first month for free, then just $2 a week for the remainder of your first year.